Repurposing riluzole as an anti-osteosarcoma agent

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Osteosarcoma exhibits significant genetic heterogeneity, complicating treatment strategies.
• Glutamate signaling plays a role in osteosarcoma progression and invasion.
• Riluzole, a glutamate-release inhibitor, is explored for its anti-cancer potential.

Purpose of the Study:

• To evaluate the efficacy of riluzole as a novel anti-osteosarcoma agent.
• To investigate riluzole's effects on diverse osteosarcoma cell lines, including patient-derived xenografts (PDX).
• To elucidate the mechanisms underlying riluzole's anti-tumor activity.

Main Methods:

• Tested riluzole's effects on 11 osteosarcoma cell lines and 4 PDX cell lines.
• Assessed glutamate secretion and invasive abilities of cell lines.
• Measured effects of riluzole on cell growth, invasion, and matrix metalloprotease-2 (MMP2) activity.

Main Results:

• Most osteosarcoma cell lines and PDX cells secreted glutamate and were invasive.
• Riluzole significantly inhibited cell growth and invasion in all tested cell lines.
• Riluzole suppressed MMP2 activity in most osteosarcoma cell lines, but not in PDX cells.

Conclusions:

• Riluzole demonstrates broad efficacy against diverse osteosarcoma cell lines, including primary and metastatic types.
• Inhibition of MMP2 activity may contribute to riluzole's anti-invasive effects.
• Riluzole is a promising candidate for preclinical studies in osteosarcoma treatment.